Most importantly, inflammatory cytokines, including IL‐6, IL‐17, VEGF, and IFN‐α, might be novel biomarkers for predicting the survival prognosis of patients with advanced HCC and PVTT receiving TACE+LEN + PD‐1 treatment. This evidence concerns the gene IL17A and hepatocellular carcinoma.